Efficacy and Safety of Liposomal Doxorubicin Combined with Vinorelbine in the Treatment of Advanced Metastatic Breast Cancer: a Single-Center, Prospective Phase II Clinical Study

With advancements in various treatment modalities, the survival of breast cancer patients has continuously improved. Patients with advanced breast cancer who have undergone multiple lines of therapy still have treatment options, but standard treatment protocols are lacking. Anthracyclines are a cornerstone in breast cancer treatment; however, their cumulative dose-related cardiac toxicity limits their use. Liposomal doxorubicin exhibits comparable efficacy to conventional anthracyclines and is not affected by previous cumulative doses. The combination of vinorelbine with liposomal doxorubicin shows reduced cross-toxicity, and several studies have demonstrated the effectiveness of this regimen in metastatic HER2-negative breast cancer patients.
Therefore, we aim to explore whether optimizing the dosage and treatment cycle of this combination therapy can provide a viable treatment option for metastatic HER2-negative breast cancer patients who have previously received second-line or higher chemotherapy, seeking a regimen that balances efficacy and safety.
This study is a single-center, single-arm Phase II clinical trial planned to enroll 30 metastatic HER2-negative breast cancer patients who have previously undergone second-line or higher chemotherapy. Participants will receive an optimized regimen of liposomal doxorubicin combined with vinorelbine, with safety assessed every cycle and efficacy evaluated every three cycles. Treatment will continue until radiographic evidence indicates disease progression, intolerable toxicity occurs, informed consent is withdrawn, or the investigator decides to discontinue treatment. Following treatment, each participant will undergo survival follow-up every three months until death, loss to follow-up, or withdrawal of consent.

开始日期2024-11-01

申办/合作机构

中国医学科学院肿瘤医院

[+1]

NCT06188494 / RecruitingN/A

A Multicenter, Observational, Secondary Data Collection, Retrospective, National Study to Assess the Prevalence of HER2-low Breast Cancer Among Patients Previously Diagnosed With Unresectable and/or Metastatic HER2-Negative Breast Cancer in Egypt - UNFOLD

Breast cancer is a major public health concern worldwide. In Egypt, it was the most diagnosed cancer among females in 2020 with an incidence rate of 32.4%. Its age-standardized incidence and mortality rates were 48.7 and 20.4 per 100,000 population, respectively. The status quo of HER2 testing in Egypt is that all breast cancer cases are tested for HER2 protein expression on the surface of tumor cells by immunohistochemistry (IHC), and only those with score 2 (equivocal) and selected cases of score 3 are subjected for further analysis using in-situ hybridization technique (ISH) to detect HER2 gene amplification in tumor nuclei.

开始日期2024-05-13

申办/合作机构

AstraZeneca PLC

NCT06131424 / RecruitingN/A

Multicentre NIS Retrospective Study to Know the Prevalence of HER2- Low,Clinical Characteristics,Treatment Patterns,Associated Outcome in Patient With HER2-negative in Metastatic Breast Cancer Who Progressed on Systemic Anticancer Therapy

This noninterventional, multicenter,retrospective study has been proposed to estimate the prevalence, clinicopathological characteristics,treatment patterns and clinical outcomes of human epidermal growth factor receptor 2 -(HER2)low locally-advanced or metastatic breast cancer(mBC) by accurate rescoring of archived IHC-stained formalin-fixed paraffin-embedded (FFPE) slides for HER2 in patients previously identified as HER2-negative from emerging markets of international regions (non-US and non-European region) with largely unknown prevalence estimates of HER2 low mBCs. Patients with a confirmed diagnosis of HER2-negative, locally-advanced or mBC regardless of Hormone receptor (HR)status between 01 January 2019 and 31 December 2022 who progressed on any systematic anticancer therapy (eg, ET, chemotherapy, CDK4/6 inhibitor, targeted therapies other than anti-HER2, or immunotherapy) in advanced disease with availability of atleast 12 months of follow-up data (from the index date) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis of locally-advanced or mBC will be enrolled in the study. The HR positive patients will be considered eligible for the study if they have received ET as adjuvant therapy in the early BC setting and progressed within 24 months. This scenario will be considered as progression on systematic treatment in the advanced or metastatic setting.

开始日期2024-04-23

申办/合作机构

AstraZeneca PLC

100 项与转移性HER2阴性乳腺癌相关的临床结果

登录后查看更多信息

100 项与转移性HER2阴性乳腺癌相关的转化医学

登录后查看更多信息

0 项与转移性HER2阴性乳腺癌相关的专利（医药）

登录后查看更多信息

242

项与转移性HER2阴性乳腺癌相关的文献（医药）

2024-09-01·Nature Medicine

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial

Article

作者: Yan, Xiaoyan ; Sun, Xiaoying ; Ge, Hewei ; Ma, Fei ; Zhai, Jingtong ; Mo, Hongnan ; Yu, Lanlan ; Qian, Haili ; Zhu, Aihua ; Wang, Jinjing ; Yu, Yongpei ; Xu, Binghe ; Guan, Xiuwen ; Wei, Yuhan

It remains unclear whether metronomic chemotherapy is superior to conventional chemotherapy when combined with immune checkpoint blockade. Here we performed a phase 2 clinical trial of metronomic chemotherapy combined with PD-1 blockade to compare the efficacy of combined conventional chemotherapy and PD-1 blockade using Bayesian adaptive randomization and efficacy monitoring. Eligible patients had metastatic HER2-negative breast cancer and had not received more than one prior line of standard chemotherapy. Patients (total n = 97) were randomized to receive (1) metronomic vinorelbine (NVB) monotherapy (n = 11), (2) NVB plus anti-PD-1 toripalimab (n = 7), (3) anti-angiogenic bevacizumab, NVB and toripalimab (n = 27), (4) conventional cisplatin, NVB and toripalimab (n = 26), or (5) metronomic cyclophosphamide, capecitabine, NVB and toripalimab (the VEX cohort) (n = 26). The primary endpoint was disease control rate (DCR). Secondary objectives included progression-free survival (PFS) and safety. The study met the primary endpoint. The VEX (69.7%) and cisplatin (73.7%) cohorts had the highest DCR. The median PFS of patients in the VEX cohort was the longest, reaching 6.6 months, followed by the bevacizumab (4.0 months) and cisplatin (3.5 months) cohorts. In general, the five regimens were well tolerated, with nausea and neutropenia being the most common adverse events. An exploratory mass cytometry analysis indicated that metronomic VEX chemotherapy reprograms the systemic immune response. Together, the clinical and translational data of this study indicate that metronomic VEX chemotherapy combined with PD-1 blockade can be a treatment option in patients with breast cancer. ClinicalTrials.gov Identifier: NCT04389073 .

2024-08-01·Clinical Breast Cancer

Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Article

作者: Karaçin, Cengiz ; Öner, İrem ; Önder, Tuğba ; Ateş, Öztürk

AIMS AND OBJECTIVESAlthough cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i) are a vital part of the treatment of hormone receptor (HR)-positive/HER-2-negative metastatic breast cancer (BC), individuals have different sensitivities to CDK4/6i, indicating the need for biomarkers. The fasting triglyceride glucose (TyG) index is an easily accessible surrogate marker of insulin resistance (IR). Herein, we investigated the prognostic significance of the fasting triglyceride glucose (TyG) index in HR+/HER2- metastatic BC patients treated with CDK4/6i plus endocrine therapy (ET).METHODSAbout 333 patients with HR+/HER2-metastatic BC treated with CDK4/6i plus ET were analyzed retrospectively. The TyG index was calculated within 3 months before the initiation of CDK4/6i plus ET. The median value of 8.43 was taken as the cutoff for the TyG index.RESULTSThe median overall survival (OS) was 73.6 months (95% CI, 66.0-81.1) in the whole cohort. The progression-free survival (PFS) was significantly longer in the low-TyG subgroup than in the high-TyG subgroup (30.1 vs. 21.3 months, multivariate adjusted [HR] = 0.666, 95% CI, 0.450-0.987, P = .043). While the median OS was not reached in the low TyG subgroup, it was 69.0 months in the high TyG subgroup (multivariate-adjusted HR = 0.513, 95% CI, 0.281-0.936, P = .030). Although the ORR and DCR were numerically greater in the low-TyG subgroup, no significant differences were observed between the low-TyG subgroup and high-TyG subgroup (28.1% vs. 24.7%, P = .476; 83.2% vs. 80.1%, P = .463, respectively).CONCLUSIONSThese data imply that the TyG index could be a predictive biomarker for the therapeutic efficacy of CDK4/6is. Extensive prospective studies are needed to confirm these findings.

2024-08-01·Clinical Breast Cancer

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer

Article

作者: Anders, Carey K. ; Dees, E. Claire ; Moore, Dominic T ; Reeder-Hayes, Katherine ; Muss, Hyman B. ; Force, Jeremy ; Moore, Dominic T. ; Marcom, P Kelly ; Abdou, Yara ; Dees, E Claire ; File, Danielle M ; File, Danielle M. ; Anders, Carey K ; Perou, Charles M ; Marcom, P. Kelly ; Carey, Lisa A ; Perou, Charles M. ; Carey, Lisa A. ; Muss, Hyman B

BACKGROUNDAlpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. The tolerability of this drug with the oral chemotherapy capecitabine is unknown.PATIENTS AND METHODSThis phase I trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of alpelisib (250 mg or 300 mg daily for 3-weeks) with capecitabine (1000 mg/m² twice daily for 2-weeks followed by a 1-week rest period) in patients with metastatic HER2-negative breast cancer, regardless of PIK3CA mutation status.RESULTSEighteen patients were treated with alpelisib-capecitabine. Half of the patients had HR+ breast cancer, and 16 had prior systemic therapy for metastatic disease. The MTD of alpelisib was 250 mg daily in combination with capecitabine 1000 mg/m² twice daily. DLTs included hyperglycemia, QTc prolongation, fatigue, and chest pain. The most common grade 3 adverse event (AE) was hyperglycemia (28%). No grade 4 AEs were observed. Three patients discontinued therapy due to an AE. One-third of patients required dose reduction of both alpelisib and capecitabine. Four patients experienced a partial response and 8 patients experienced stable disease. The median progression-free survival was 9.7 months (95% CI 2.8-13.5 months) and median overall survival was 18.2 months (95% CI 7.2-35.2 months). Twelve patients had PIK3CA mutation testing completed, of these 2 had known or likely deleterious PIK3CA mutation.CONCLUSIONThis study provides safety data for an oral combination therapy of alpelisib-capecitabine and defines tolerable doses for further study.

项与转移性HER2阴性乳腺癌相关的新闻（医药）

2024-10-26

·三生制药

三生制药与海和药物就紫杉醇口服溶液达成合作

10月24日，三生制药与上海海和药物研究开发股份有限公司（以下简称：海和药物）在上海举行合作签约仪式。三生制药子公司沈阳三生制药有限责任公司（以下简称：沈阳三生）获得海和药物子公司诺迈西（上海）医药科技有限公司（以下简称：诺迈西医药）旗下产品紫杉醇口服溶液的独家商业化权利（中国大陆及中国香港地区）。根据协议，沈阳三生将向诺迈西医药支付首付款、研发及销售里程碑付款。诺迈西医药将继续负责已开展的III期临床试验及产品后续的开发、临床及注册等工作。紫杉醇是一种生物碱类化合物，具有显著的抗癌活性，能够通过干扰肿瘤细胞的有丝分裂和阻止其生长来发挥作用。临床上，紫杉醇被广泛用于胃癌、乳腺癌、非小细胞肺癌等多种恶性肿瘤的治疗。紫杉醇口服溶液由韩国大化制药基于脂质自乳化药物递送技术开发而成，已获得韩国食品与药品监督局（MFDS）上市批准，用于晚期或转移性或局部复发性胃癌二线治疗，是全球第一款获批的口服剂型紫杉醇药物。海和药物自韩国大化制药获得了紫杉醇口服溶液在中国及泰国的研发、生产及销售权利。今年9月25日，海和药物和韩国大化制药共同宣布，双方合作开发的紫杉醇口服溶液2024年9月19日获得中国国家药监局批准上市，适用于一线含氟尿嘧啶类方案治疗期间或治疗后出现疾病进展的晚期胃癌患者的治疗。一项在国内进行的开放、随机平行对照、非劣效设计、多中心Ⅲ期研究（CTR20190050）显示，紫杉醇口服溶液在经一线治疗后的不可手术切除、复发或转移性晚期胃癌患者中，疗效优于紫杉醇注射液，中位总生存时间延长了2.59个月（HR：0.770, p=0.006），且整体安全耐受。现阶段，该药作为一线化疗（既往未接受系统化疗）治疗复发性或转移性HER2阴性乳腺癌适应症的国际多中心III期临床研究也在顺利进行中。此前，国内紫杉醇的上市剂型均为注射剂，需经配制后在医院经静脉滴注给药，患者需频繁返院，且会有注射部位不良反应；口服剂型的紫杉醇药物给患者带来口服便捷的同时，提高了临床疗效，降低脱发、外周神经病变、疲乏和过敏反应等不良反应的发生率，显著提高患者的生活质量。三生制药董事长兼首席执行官娄竞博士表示：“紫杉醇在肿瘤治疗中有广泛的应用场景，口服溶液剂型是该经典药物的又一次重大突破性创新，在提高相关疾病患者生存率的同时，为患者提供了更便利的给药方式，大大降低了化疗给患者造成的痛苦。海和药物在引入该药的基础上进行了进一步的开发，不断扩大口服剂型的使用范围，已成功获批胃癌二线治疗适应症。我们很高兴能和海和药物合作，一起让更多患者用上这一新药、好药，共同增益患者的福祉，让这款新药为患者带去更大的价值。” 海和药物首席执行官董瑞平博士表示：“很高兴与三生制药达成战略合作。海和药物一直聚焦抗肿瘤治疗领域，致力于给患者带来更好的药物。紫杉醇类药物在实体瘤治疗中应用广泛，但一直没有在剂型上得到突破。紫杉醇口服溶液作为中国首个上市的口服剂型紫杉醇类药物，将显著延长胃癌患者生存时间，让患者更方便更安全地使用。三生制药作为中国领先的生物技术公司，具有高效的推广团队和强大的商业化能力，与紫杉醇口服溶液巨大的临床价值深度契合，将惠及广大的肿瘤患者。同时，我们也期待双方充分发挥各自的优势，继续推进药物在研究、临床开发等方面的潜在合作，为患者带来创新的治疗选择。” 三生制药是一家集研发、生产和销售为一体的生物制药领军企业，致力于以高品质的药品提高患者生存质量，为人类健康造福。目前，公司拥有100余项国家发明专利授权，40余种上市产品，覆盖肾科、肿瘤科、自身免疫性疾病、眼科及皮肤科等多种治疗领域。公司拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心，共有28种在研产品，其中25种为国家新药，并拥有符合GMP标准的5大生产基地。未来，三生制药将继续秉持“珍爱生命、关注生存、创造生活”的理念，全力打造全球领先的中国生物制药企业。请访问www.3sbio.com获取更多信息。海和药物是中国领先的自主创新生物技术公司，专注于抗肿瘤创新药物的发现、开发、生产及商业化，希望为全球癌症患者带来更安全、更有效的治疗方法。海和药物坚持走自主创新的道路，同时拥有一支具有全球化视野的科研和管理团队，积极布局创新药物的国际开发之路。目前海和药物已有2款产品获准上市：1.谷美替尼片，中文商品名：海益坦®；日本商品名：ハイイータン®錠50㎎，已正式在中国和日本均获批上市；2.紫杉醇口服溶液已正式在中国获批上市。另，海和药物同时有多个在研重点管线的候选药物。内容来源于网络，如有侵权，请联系删除。

上市批准引进/卖出医药出海

2024-10-12

·医药观澜

PARP抑制剂「奥拉帕利」新适应症在华申报上市

▎药明康德内容团队报道 10月11日，中国国家药监局药品审评中心（CDE）官网公示，阿斯利康（AstraZeneca）和艾伯维（AbbVie）共同申报的奥拉帕利片上市申请获得受理。公开资料显示，奥拉帕利（olaparib）是一款PARP抑制剂，由阿斯利康与默沙东（MSD）联合开发和商业化。截图来源：CDE官网奥拉帕利是一款“first-in-class”PARP抑制剂，是一款阻断同源重组修复（HRR）缺陷（例如BRCA1和/或BRCA2突变，或由其他药物新型内分泌药物引起的缺陷）的细胞/肿瘤中DNA损伤修复通路（DDR）的靶向治疗药物。使用奥拉帕利抑制PARP可导致PARP与DNA单链断裂结合，从而阻止复制叉的形成和崩塌，并导致DNA双链断裂和癌细胞死亡。奥拉帕利还可能有助于增强免疫原性并增加抗肿瘤免疫反应的影响。公开资料显示，奥拉帕利由阿斯利康和默沙东联合开发和商业化，既可作为单一疗法使用，也可与其他潜在药物联合使用。两家公司正在独立开发奥拉帕利并将其与各自的PD-L1和PD-1药物度伐利尤单抗和帕博利珠单抗联合使用。阿斯利康和默沙东正在共同探索其作为单一疗法和联合疗法对多种癌症类型PARP依赖性肿瘤的影响。根据阿斯利康近期新闻稿介绍，目前奥拉帕利已在多个国家获批用于多个肿瘤类型，包括：铂敏感复发性卵巢癌的维持治疗，以及作为单药治疗和与贝伐单抗联合用于BRCA突变 (BRCAm) 和同源重组修复缺陷 (HRD) 阳性晚期卵巢癌的一线维持治疗；用于胚系BRCA突变 (gBRCAm），HER2阴性转移性乳腺癌（在欧盟和日本，包括局部晚期乳腺癌）；用于gBRCAm，HER2阴性高危早期乳腺癌（在日本，包括所有BRCAm HER2阴性高危早期乳腺癌）；用于gBRCAm转移性胰腺癌；与阿比特龙联合用于临床无化疗指征的转移性去势抵抗性前列腺癌 (mCRPC) 治疗（仅限欧盟）和BRCAm mCRPC（美国和日本）；作为HRR基因突变mCRPC的单药疗法，用于既往NHA治疗后出现进展的患者（BRCAm仅在欧盟和日本有效）。在中国，奥拉帕利于2018年首次获批上市，用于铂敏感复发性卵巢癌患者的维持治疗。此后该产品陆续在中国获批多个适应症，包括BRCA突变晚期卵巢癌一线维持治疗、携带胚系或体细胞BRCA突变且既往治疗失败的转移性去势抵抗性前列腺癌成人患者的治疗、与贝伐珠单抗联合用于HRD阳性晚期卵巢癌一线维持治疗。2024年1月，奥拉帕利单药或与内分泌治疗联合用于胚系BRCA1/2突变的HER2阴性早期高危乳腺癌成人患者的辅助治疗新适应症上市申请也获得受理。根据中国药物临床试验与信息公示平台官网，研究人员正在进行十多项奥拉帕利相关的3期临床研究，其中正在进行中的3期临床研究包括了：一项在接受标准一线含铂化疗后达到缓解的BRCA野生型晚期（FIGO III-IV期）高级别浆液性或子宫内膜样卵巢癌受试者中进行的奥拉帕利单药的国际多中心3期研究（MONO-OLA1）；一项国际多中心3期临床研究（DUO-O），旨在确定新诊断的晚期无肿瘤BRCA突变的上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者中度伐利尤单抗和奥拉帕利的疗效；在含铂化疗后CR或PR铂敏感复发卵巢癌患者中评价奥拉帕利单药维持治疗疗效的国际多中心3期研究；评估奥拉帕利针对gBRCA1/2突变且高危HER2阴性原发性乳腺癌患者的疗效和安全性的国际多中心3期研究；评价一线铂化疗后奥拉帕利在BRCA突变晚期卵巢癌患者中单药维持治疗的安慰剂对照国际多中心3期研究。本次奥拉帕利在中国申报新适应症上市申请，意味着该产品在中国的研发迎来新的进展。参考资料： [1]中国国家药监局药品审评中心（CDE）官网. Retrieved Oct 11，2024, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2]利普卓和英飞凡组合疗法在欧盟获批用于治疗错配修复功能正常的晚期或复发性子宫内膜癌患者. Retrieved Aug 15，20234, From https://www.astrazeneca.com.cn/zh/media/press-releases/2024/08-15-01.html 本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准临床结果申请上市临床研究

2024-09-30

·FierceBiotech

Roche celebrates Pharma Day by buying Regor's CDK inhibitors, regenerative med-focused AntlerA

Buying RGT-419B continues Roche’s push into HR-positive breast cancer. Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options. The deal was announced on Roche's Pharma Day, where the Swiss Big Pharma—which owns Genentech—also disclosed (PDF) the acquisition of Wnt signaling-focused biotech AntlerA Therapeutics.Regor, a Chinese-American biotech, presented phase 1a results on its next-generation CDK inhibitor late last year. The biotech designed the drug candidate to have high potency against CDK4, additional activity versus CDK2 and selectivity against CDK6. Those features are intended to overcome resistance to CDK4/6 inhibition and reduce hematologic toxicity.The biotech is testing the molecule, which is called RGT-419B, in hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer patients who progressed on prior CDK4/6 inhibitors. All 12 of the women in the analysis had previously received Pfizer’s CDK4/6 inhibitor Ibrance. Two patients had also taken Novartis’ Kisqali or Eli Lilly’s Verzenio, other approved CDK inhibitors.Regor saw (PDF) two confirmed and one unconfirmed partial responses during dose escalation. The monotherapy’s 28.6% confirmed partial response rate in seven patients with measurable disease, plus absence of grade 3 or higher adverse events, led Regor to plan dose expansions of RGT-419B as a single agent and in combination with endocrine therapy. The biotech will manage two ongoing phase 1 trials of RGT-419B to completion. After that, Genentech will be responsible for clinical development, manufacturing and commercialization worldwide. As the CDK inhibitors advance, Genentech could pay development, regulatory and commercial milestones of undisclosed size.Buying RGT-419B continues Roche’s push into HR-positive breast cancer, which represents around 70% of all cases. The Swiss drugmaker is developing giredestrant, a selective endocrine receptor degrader, and inavolisib, a PI3K inhibitor, in HR-positive disease. Roche sees giredestrant as a potential replacement for endocrine therapies that combines tolerably with CDK inhibitors. The ability to combine inavolisib with CDK inhibitors is central to Roche’s attempt to differentiate the PI3K inhibitor.To date, Roche has paired its candidates with CDK inhibitors from Lilly, Novartis and Pfizer. Genentech’s acquisition of the Regor portfolio, which is expected to close in the fourth quarter, will give Roche its own CDK inhibitors.After selling the CDK inhibitor portfolio, Regor will focus on its remaining oncology, metabolic disease and autoimmune assets. The pipeline is led by an oral GLP-1 receptor agonist that is in clinical development in diabetes and obesity. Lilly partnered with the biotech to work on metabolic disorders in 2021. Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library of anti-FZD/LRP drug candidates. Roche sees AntlerA’s preclinical lead asset as a potential best-in-class treatment for neovascular age-related macular degeneration and diabetic macular edema.Roche wouldn't disclose the financial details of the deal, but a spokesperson told Fierce Biotech that the biotech's pipeline is “a strong fit with our interest in ophthalmology and ... the Wnt pathway could be very promising for the treatment of other diseases.”Today's oncology and eye-focused deals strengthen Roche’s pipeline in two of the five priority areas for its new pharma strategy, which the company reaffirmed at its Pharma Day in London this morning. Roche’s 10-year ambition is to deliver 20 transformative medicines addressing diseases with the highest societal burden, executives explained to attendees at the event.